HC Wainwright Has Positive Forecast for NRIX Q2 Earnings

Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report) - Equities researchers at HC Wainwright increased their Q2 2025 earnings estimates for Nurix Therapeutics in a research note issued to investors on Tuesday, July 1st. HC Wainwright analyst R. Burns now expects that the company will earn ($0.62) per share for the quarter, up from their previous estimate of ($0.74). HC Wainwright currently has a "Buy" rating and a $36.00 price target on the stock. The consensus estimate for Nurix Therapeutics' current full-year earnings is ($2.99) per share. HC Wainwright also issued estimates for Nurix Therapeutics' FY2025 earnings at ($2.83) EPS, Q1 2026 earnings at ($0.80) EPS, Q2 2026 earnings at ($0.82) EPS, Q3 2026 earnings at ($0.84) EPS and Q4 2026 earnings at ($0.87) EPS.

Nurix Therapeutics (NASDAQ:NRIX - Get Free Report) last posted its quarterly earnings data on Tuesday, April 8th. The company reported ($0.67) earnings per share for the quarter, beating the consensus estimate of ($0.72) by $0.05. Nurix Therapeutics had a negative net margin of 369.40% and a negative return on equity of 47.49%. The firm had revenue of $18.45 million for the quarter, compared to analysts' expectations of $12.78 million. During the same quarter last year, the company posted ($0.76) EPS.

Several other equities research analysts have also issued reports on NRIX. Needham & Company LLC reaffirmed a "buy" rating and set a $27.00 price target on shares of Nurix Therapeutics in a research note on Tuesday, April 29th. Wells Fargo & Company dropped their target price on Nurix Therapeutics from $32.00 to $25.00 and set an "overweight" rating for the company in a research report on Wednesday, April 9th. Leerink Partners started coverage on Nurix Therapeutics in a research note on Monday, March 17th. They issued a "market perform" rating and a $16.00 target price for the company. Stifel Nicolaus reduced their price target on shares of Nurix Therapeutics from $36.00 to $35.00 and set a "buy" rating on the stock in a research report on Wednesday, April 9th. Finally, Leerink Partnrs upgraded shares of Nurix Therapeutics to a "hold" rating in a research report on Monday, March 17th. Four investment analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $30.18.

Nurix Therapeutics Stock Performance

NRIX traded up $0.29 during trading on Thursday, reaching $12.73. The stock had a trading volume of 279,635 shares, compared to its average volume of 836,838. The business has a 50-day moving average of $11.12 and a 200-day moving average of $14.01. Nurix Therapeutics has a one year low of $8.18 and a one year high of $29.56. The stock has a market cap of $970.54 million, a PE ratio of -4.55 and a beta of 2.15.

Insider Buying and Selling

In related news, CFO Houte Hans Van sold 6,198 shares of the company's stock in a transaction that occurred on Friday, May 2nd. The stock was sold at an average price of $11.33, for a total transaction of $70,223.34. Following the completion of the transaction, the chief financial officer owned 33,724 shares in the company, valued at $382,092.92. This represents a 15.53% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Gwenn Hansen sold 3,377 shares of Nurix Therapeutics stock in a transaction on Wednesday, April 30th. The shares were sold at an average price of $11.50, for a total transaction of $38,835.50. Following the completion of the sale, the insider owned 61,516 shares in the company, valued at approximately $707,434. This trade represents a 5.20% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 12,013 shares of company stock worth $137,096. Corporate insiders own 7.40% of the company's stock.

Institutional Investors Weigh In On Nurix Therapeutics

A number of large investors have recently modified their holdings of the stock. FMR LLC lifted its holdings in Nurix Therapeutics by 1,711.9% in the fourth quarter. FMR LLC now owns 10,634,231 shares of the company's stock worth $200,349,000 after buying an additional 10,047,329 shares during the period. RA Capital Management L.P. bought a new position in shares of Nurix Therapeutics in the 4th quarter worth approximately $25,120,000. Soleus Capital Management L.P. raised its position in shares of Nurix Therapeutics by 97.3% in the 4th quarter. Soleus Capital Management L.P. now owns 2,102,833 shares of the company's stock worth $39,617,000 after acquiring an additional 1,036,999 shares in the last quarter. Point72 Asset Management L.P. purchased a new position in shares of Nurix Therapeutics in the 4th quarter valued at approximately $16,447,000. Finally, Vestal Point Capital LP boosted its position in shares of Nurix Therapeutics by 132.1% during the first quarter. Vestal Point Capital LP now owns 1,125,552 shares of the company's stock valued at $13,372,000 after purchasing an additional 640,552 shares in the last quarter.

About Nurix Therapeutics

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.